Robert Zeiser

Prof. Dr.
Principal Investigator

Center for Medicine
Department of Medicine I
Medical Center – University of Freiburg

Hugstetter Straße 55
79106 Freiburg i. Brsg.

Current position

Professor, Heisenberg Group leader, Department of Medicine I, Center for Medicine,

Medical Center – University of Freiburg

Academic training

1995 – 2001 Study of Medicine in Freiburg, Germany

Scientific qualifications

2010 Habilitation in Internal Medicine, University of Freiburg
(Mentor: Prof. R. Mertelsmann)
2001 Dissertation in Medicine, University of Freiburg (Dept. of Pathology) (Supervisor: Prof. H.E. Schaefer)

Postgraduate Positions

since 2019 Director (Abteilungsleiter) Division of Tumor immunology
since 2016 Section Head of Tumor immunology within Internal Medicine I
since 2013 Heisenberg Professorship in Hematology and Oncology
since 2010 Senior physician, Division of Hemataology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg
2007 – 2010 Assistant physician, Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center – University of Freiburg
2005 – 2007 Postdoctorate, Stanford University School of Medicine, BMT Department, USA
2001 – 2004 Internship in Internal Medicine, Department of Hematology, Oncology and Stem Cell Transplantation,
Medical Center – University of Freiburg

Miscellaneous (Honors, Awards)

2024 DKMS Mechtild Harf Science Award
2022 DGIM Prevention Prize
2021 Deutscher Krebspreis
2020 Preis der Berlin-Brandenburgischen Akademie der Wissenschaften
2019 Paul-Martini-Award
2017 Richtzenhain Cancer Research Award (DKFZ)
2015 Jon van Rood Award (European Soc. for Blood & Marrow Transplantation)
2014 Artur Pappenheim Award (Dt. Gesellschaft für Hämatologie/Onkologie)
2014 Hans-Jochem Kolb Award
2012 Science Award (DAG-Knochenmark und Blutstammzelltransplantation)
2011 Theodor-Frerichs-Prize (Deutsche Gesellschaft für Innere Medizin)
2011 Heisenberg Scholarship (DFG)
2008 Eugen-Graetz-Prize for translational research,
University of Freiburg
2008 BBMT Editorial Award (best basic science article)
2007 Best Abstract Award, XXIII Symposium of the IACRLRD
2006 American Society of Hematology Scholar Award
2006 Trainee Research Award, American Society of Hematology

link to all publications from R. Zeiser: Pubmed

Publications based on CRC1160 funding

Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher LS, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert AL, Schramm MA, Cheng Y, Köttgen A, Duyster J, Menssen HD, Ritz J, Blazar BR, Boerries M, Schmitt Graeff A, Sariipek N, van Galen P, Buescher JM, Cabezas-Wallscheid N, Pahl HL, Pearce EL, Soiffer RJ, Wu CJ, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R. 2024. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. J Clin Invest. e177460. doi: 10.1172/JCI177460.

Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, Staehle HF, Vinnakota JM, Duquesne S, Mozaffari Jovein M, Pfeifer D, Becker H, Blazar BR, Zähringer A, Duyster J, Brummer T, Boerries M, Baumeister J, Shoumariyeh K, Li J, Green AR, Heidel FH, Tirosh I, Pahl HL, Leimkühler N, Köhler N, de Toledo MAS, Koschmieder S, Zeiser R. 2024. Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF-β Expression and Regulatory T Cell Expansion in the Bone Marrow Microenvironment. Cancer Res. doi: 10.1158/0008-5472.CAN-23-3553.

Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. 2024. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer. May 13. doi: 10.1038/s43018-024-00764-7.

Czech M, Schneider S, Peltokangas N, El Khawanky N, Ghimire S, Andrieux G, Hülsdünker J, Krausz M, Proietti M, Braun LM, Rückert T, Langenbach M, Schmidt D, Martin I, Wenger V, de Vega E, Haring E, Pourjam M, Pfeifer D, Schmitt-Graeff A, Grimbacher B, Aumann K, Kircher B, Tilg H, Raffatellu M, Thiele Orberg E, Häcker G, Duyster J, Köhler N, Holler E, Nachbaur D, Boerries M, Gerner RR, Grün D, Zeiser R. 2024. Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease. Sci Transl Med. 2024 Feb 21;16(735):eadi1501. doi: 10.1126/scitranslmed.adi1501.

Wertheimer T, Zwicky P, Rindlisbacher L, Sparano C, Vermeer M, de Melo BMS, Haftmann C, Rückert T, Sethi A, Schärli S, Huber A, Ingelfinger F, Xu C, Kim D, Häne P, Fonseca da Silva A, Muschaweckh A, Nunez N, Krishnarajah S, Köhler N, Zeiser R, Oukka M, Korn T, Tugues S, Becher B. 2024. IL-23 stabilizes an effector Treg cell program in the tumor microenvironment. Nat Immunol. 25(3):512-524. doi: 10.1038/s41590-024-01755-7.

Maas-Bauer K, Stell AV, Yan KL, de Vega E, Vinnakota JM, Unger S, Núñez N, Norona J, Talvard-Balland N, Koßmann S, Schwan C, Miething C, Martens US, Shoumariyeh K, Nestor RP, Duquesne S, Hanke K, Rackiewicz M, Hu Z, El Khawanky N, Taromi S, Andrlova H, Faraidun H, Walter S, Pfeifer D, Follo M, Waldschmidt J, Melchinger W, Rassner M, Wehr C, Schmitt-Graeff A, Halbach S, Liao J, Häcker G, Brummer T, Dengjel J, Andrieux G, Grosse R, Tugues S, Blazar BR, Becher B, Boerries M, Zeiser R. 2024. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nat Commun. 15(1):446. doi: 10.1038/s41467-024-44703-7.

Frueh JT, Campe J, Sunaga-Franze DY, Verheyden NA, Ghimire S, Meedt E, Haslinger D, Harenkamp S, Staudenraus D, Sauer S, Kreft A, Schubert R, Lohoff M, Krueger A, Bonig H, Chiocchetti AG, Zeiser R, Holler E, Ullrich E. 2023. Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis. Oncoimmunology. 13(1):2296712. doi: 10.1080/2162402X.2023.2296712.

Sankowski R, Süß P, Benkendorff A, Böttcher C, Fernandez-Zapata C, Chhatbar C, Cahueau J, Monaco G, Gasull AD, Khavaran A, Grauvogel J, Scheiwe C, Shah MJ, Heiland DH, Schnell O, Markfeld-Erol F, Kunze M, Zeiser R, Priller J, Prinz M. 2023. Multiomic spatial landscape of innate immune cells at human central nervous system borders. Nat Med. 2023 Dec 20. doi: 10.1038/s41591-023-02673-1.

Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo Núñez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, Böke C, Pfeifer D, Marks R, Bertz H, Wäsch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R. 2023. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023 Oct;203(2):264-281. doi: 10.1111/bjh.19007.

de Maissin H, Groß PR, Mohiuddin O, Weigt M, Nagel L, Herzog M, Wang Z, Willing R, Reichardt W, Pichotka M, Heß L, Reinheckel T, Jessen HJ, Zeiser R, Bock M, von Elverfeldt D, Zaitsev M, Korchak S, Glöggler S, Hövener JB, Chekmenev EY, Schilling F, Knecht S, Schmidt AB. 2023. In Vivo Metabolic Imaging of [1-13 C]Pyruvate-d3 Hyperpolarized By Reversible Exchange With Parahydrogen. Angew Chem Int Ed Engl. 62(36):e202306654. doi: 10.1002/anie.202306654.

Wenger V, Zeiser R. 2023. Editorial: Current concepts of cellular and biological drugs to modulate regulatory T cell activity in the clinic, volume II. Front Immunol. 2023 Jun 13;14:1221904. doi: 10.3389/fimmu.2023.1221904.

Villa M, Sanin DE, Apostolova P, Corrado M, Kabat AM, Cristinzio C, Regina A, Carrizo GE, Rana N, Stanczak MA, Baixauli F, Grzes KM, Cupovic J, Solagna F, Hackl A, Globig AM, Hässler F, Puleston DJ, Kelly B, Cabezas-Wallscheid N, Hasselblatt P, Bengsch B, Zeiser R, Sagar, Buescher JM, Pearce EJ, Pearce EL. 2023. Prostaglandin E 2 controls the metabolic adaptation of T cells to the intestinal microenvironment. bioRxiv. Mar 15:2023.03.13.532431. doi: 10.1101/2023.03.13.532431.

Ruckert, T., G. Andrieux, M. Boerries, K. Hanke-Muller, N. M. Woessner, S. Doetsch, C. Schell, K. Aumann, J. Kolter, A. Schmitt-Graeff, M. Schiff, L. M. Braun, E. Haring, S. Kissel, B. A. Siranosian, A. S. Bhatt, P. Nordkild, J. Wehkamp, B. A. H. Jensen, S. Minguet, J. Duyster, R. Zeiser, and N. Kohler. 2022. Human beta-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med 14: eabp9675. doi: 10.1126/scitranslmed.abp9675.

Gruninger, P. K., F. Uhl, H. Herzog, G. Gentile, M. Andrade-Martinez, T. Schmidt, K. Han, D. W. Morgens, M. C. Bassik, M. L. Cleary, O. Gorka, R. Zeiser, O. Gross, and J. Duque-Afonso. 2022. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia. Cancer Gene Ther. pii: 10.1038/s41417-022-00491-0. doi: 10.1038/s41417-022-00491-0.

Ho, J., D. Schmidt, T. Lowinus, J. Ryoo, E. P. Dopfer, N. Gonzalo Nunez, S. Costa-Pereira, C. Toffalori, M. Punta, V. Fetsch, T. Wertheimer, M. C. Rittmann, L. M. Braun, M. Follo, C. Briere, J. M. Vinnakota, M. Langenbach, F. Koppers, K. Shoumariyeh, H. Engel, T. Ruckert, M. Marklin, S. Holzmayer, A. L. Illert, F. Magon, G. Andrieux, S. Duquesne, D. Pfeifer, J. Staniek, M. Rizzi, C. Miething, N. Kohler, J. Duyster, H. D. Menssen, M. Boerries, J. M. Buescher, N. Cabezas-Wallscheid, B. R. Blazar, P. Apostolova, L. Vago, E. L. Pearce, B. Becher, and R. Zeiser. 2022. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood 140: 1167-1181. doi: 10.1182/blood.2022016082.

Biavasco, F., G. Ihorst, R. Wasch, C. Wehr, H. Bertz, J. Finke, and R. Zeiser. 2022. Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. Bone Marrow Transplant 57: 1500-1506. doi: 10.1038/s41409-022-01741-3.

Czech M, Zeiser R, Toubai T. Front Immunol. 2022. Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation. First published: 2022 Jun 8;13:948720. doi: 10.3389/fimmu.2022.948720. eCollection 2022. PMID: 35757690 Free PMC article.

Czech M, Zeiser R, Toubai T. 2022. Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation. Front Immunol. 2022 Jun 8;13:948720. doi: 10.3389/fimmu.2022.948720.

Zeiser R, Warnatz K, Rosshart S, Sagar, Tanriver Y. 2022. GVHD, IBD and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunity. Eur J Immunol. 52(9):1406-1418. doi: 10.1002/eji.202149530.

El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R. 2021. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 12(1):6436. doi: 10.1038/s41467-021-26683-0.

Osswald L, Hamarsheh S, Uhl FM, Andrieux G, Klein C, Dierks C, Duquesne S, Braun LM, Schmitt-Graeff A, Duyster J, Boerries M, Brummer T, Zeiser R. 2021. Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice. Mol Cancer Res. 19(9):1596-1608. doi: 10.1158/1541-7786.MCR-20-0275.

Haring E, Andrieux G, Uhl FM, Krausz M, Proietti M, Sauer B, Esser PR, Martin SF, Pfeifer D, Schmitt-Graeff A, Duyster J, Köhler N, Grimbacher B, Boerries M, Aumann K, Zeiser R, Apostolova P. 2021. Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease. Haematologica. doi: 10.3324/haematol.2021.278387.

O’Sullivan D, Stanczak MA, Villa M, Uhl FM, Corrado M, Klein Geltink RI, Sanin DE, Apostolova P, Rana N, Edwards-Hicks J, Grzes KM, Kabat AM, Kyle RL, Fabri M, Curtis JD, Buck MD, Patterson AE, Regina A, Field CS, Baixauli F, Puleston DJ, Pearce EJ, Zeiser R, Pearce EL. 2021. Fever supports CD8+ effector T cell responses by promoting mitochondrial translation. Proc Natl Acad Sci U S A. 118(25):e2023752118.

Braun LM, Zeiser R. 2021. Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease. Hemasphere. 5(6):e581.

Kohler, N., D. A. Ruess, R. Kesselring, and R. Zeiser. 2021. The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation. Front Immunol 12: 634435.

Hamarsheh, S., O. Gross, T. Brummer, and R. Zeiser. 2020. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun 11: 5439.

Uhl, F. M., S. Chen, D. O’Sullivan, J. Edwards-Hicks, G. Richter, E. Haring, G. Andrieux, S. Halbach, P. Apostolova, J. Buscher, S. Duquesne, W. Melchinger, B. Sauer, K. Shoumariyeh, A. Schmitt-Graeff, M. Kreutz, M. Lubbert, J. Duyster, T. Brummer, M. Boerries, T. Madl, B. R. Blazar, O. Gross, E. L. Pearce, and R. Zeiser. 2020. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med 12:eabb8969. doi: 10.1126/scitranslmed.abb8969.

Thangavelu, G., C. Wang, M. Loschi, A. Saha, M. Osborn, S. N. Furlan, K. Aoyama, C. McDonald-Hyman, E. G. Aguilar, A. S. Janesick, R. A. Chandraratna, Y. Refaeli, A. Panoskaltsis-Mortari, K. P. MacDonald, G. R. Hill, R. Zeiser, I. Maillard, J. Serody, W. J. Murphy, D. H. Munn, B. Blumberg, C. Brown, V. K. Kuchroo, L. S. Kean, K. Hippen, R. J. Noelle, and B. R. Blazar. 2020. Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses. Blood. 137(8):1090-1103. doi: 10.1182/blood.2020005628.

Hartl FA, Beck-Garcìa E, Woessner NM, Flachsmann LJ, Cárdenas RMV, Brandl SM, Taromi S, Fiala GJ, Morath A, Mishra P, Yousefi OS, Zimmermann J, Hoefflin N, Köhn M, Wöhrl BM, Zeiser R, Schweimer K, Günther S, Schamel WW, Minguet S. 2020. Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function. Nat Immunol. 21(8):902-913. doi: 10.1038/s41590-020-0732-3. Epub 2020 Jul 20.

Haring E, Uhl FM, Andrieux G, Proietti M, Bulashevska A, Sauer B, Braun LM, de Vega Gomez E, Esser PR, Martin SF, Pfeifer D, Follo M, Schmitt-Graeff A, Buescher J, Duyster J, Grimbacher B, Boerries M, Pearce EL, Zeiser R, Apostolova P. Haematologica. 2020. Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect. Jul 16:haematol.2019.242990. doi: 10.3324/haematol.2019.242990. Online ahead of print.

Hamarsheh S, Zeiser R. 2020. NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword. Front Immunol. 8;11:1444. doi: 10.3389/fimmu.2020.01444. eCollection 2020.

Braun, L. M., and R. Zeiser. 2020. Immunotherapy in Myeloproliferative Diseases. Cells 9: E1559. doi: 10.3390/cells9061559

Norona, J., P. Apostolova, D. Schmidt, R. Ihlemann, N. Reischmann, G. Taylor, N. Kohler, J. de Heer, S. Heeg, G. Andrieux, B. A. Siranosian, A. Schmitt-Graeff, D. Pfeifer, A. Catalano, I. Frew, M. Proietti, B. Grimbacher, A. Bulashevska, A. S. Bhatt, T. Brummer, T. S. Clauditz, T. Zabelina, N. Kroeger, B. R. Blazar, M. Boerries, F. Ayuk, and R. Zeiser. 2020. Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. Blood. 2020005957. doi: 10.1182/blood.2020005957. Online ahead of print.

Hamarsheh, S., L. Osswald, B. S. Saller, S. Unger, D. De Feo, J. M. Vinnakota, M. Konantz, F. M. Uhl, H. Becker, M. Lubbert, K. Shoumariyeh, C. Schurch, G. Andrieux, N. Venhoff, A. Schmitt-Graeff, S. Duquesne, D. Pfeifer, M. A. Cooper, C. Lengerke, M. Boerries, J. Duyster, C. M. Niemeyer, M. Erlacher, B. R. Blazar, B. Becher, O. Gross, T. Brummer, and R. Zeiser. 2020. Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun 11: 1659.

Marschner, D., M. Falk, N. R. Javorniczky, K. Hanke-Muller, J. Rawluk, Schmitt-Graeff, F. Simonetta, E. Haring, S. Dicks, M. Ku, S. Duquesne, K. Aumann, D. Rafei-Shamsabadi, F. Meiss, P. Marschner, M. Boerries, R. S. Negrin, J. Duyster, R. Zeiser, and N. Kohler. 2020. MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. JCI insight 5. pii: 132334. doi: 10.1172/jci.insight.132334.

R Mathew N, Vinnakota JM, Apostolova P, Erny D, Hamarsheh S, Andrieux G, Kim JS, Hanke K, Goldmann T, Chappell-Maor L, El-Khawanky N, Ihorst G, Schmidt D, Duyster J, Finke J, Blank T, Boerries M, Blazar BR, Jung S, Prinz M, Zeiser R. 2019. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. J Clin Invest. pii: 130272.

Hulsdunker, J., O. S. Thomas, E. Haring, S. Unger, N. Gonzalo Nunez, S. Tugues, Z. Gao, S. Duquesne, C. Cywes-Bentley, O. Oyardi, S. Kirschnek, A. Schmitt-Graeff, O. Pabst, C. Koenecke, J. Duyster, P. Apostolova, M. J. Blaser, B. Becher, G. B. Pier, G. Hacker, and R. Zeiser. 2019. Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity. Proc Natl Acad Sci USA 116: 20700-20706.

Zeiser, R., and L. Vago. 2019. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 133: 1290-1297.

Mathew NR, Baumgartner F, Braun L, O’Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S,Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 24: 282-291.

Prestipino A, Emhardt AJ, Aumann K, O’Sullivan D, Gorantla SP, Duquesne S,Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M,Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R. 2018. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 10(429). pii:eaam7729.

Hulsdunker, J., K. J. Ottmuller, H. P. Neeff, M. Koyama, Z. Gao, O. S. Thomas, M. Follo, A. Al-Ahmad, G. Prinz, S. Duquesne, H. Dierbach, S. Kirschnek, T. Lammermann, M. J. Blaser, B. T. Fife, B. R. Blazar, A. Beilhack, G. R. Hill, G. Hacker, and R. Zeiser. 2018. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood. 131(16):1858-1869.

Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R. 2017. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia. 31(12):2732-2741.

Goldmann T, Wieghofer P, Jordão MJ, Prutek F, Hagemeyer N, Frenzel K, Amann L, Staszewski O, Kierdorf K, Krueger M, Locatelli G, Hochgerner H, Zeiser R, Epelman S, Geissmann F, Priller J, Rossi FM, Bechmann I, Kerschensteiner M, Linnarsson S, Jung S, Prinz M. 2016. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat Immunol. 17(7):797-805.

Apostolova P, Zeiser R. 2016. The role of danger signals and ectonucleotidases in acute graft-versus-host disease. Hum Immunol. 77(11):1037-1047.

Schönle A, Hartl FA, Mentzel J, Nöltner T, Rauch KS, Prestipino A, Wohlfeil SA, Apostolova P, Hechinger AK, Melchinger W, Fehrenbach K, Guadamillas MC, Follo M, Prinz G, Ruess AK, Pfeifer D, del Pozo MA, Schmitt-Graeff A, Duyster J, Hippen KI, Blazar BR, Schachtrup K, Minguet S, Zeiser R. 2016. Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. Blood. 127:1930-1939.